#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1. Introduction
1-1	0-2	1.	_	_	_	_
1-2	3-15	Introduction	abstract	new	_	_

#Text=Obesity and vitamin-D deficiency are two major global public health concerns that affect over one-third of the population .
2-1	16-23	Obesity	abstract	new	coref	7-16[49_0]
2-2	24-27	and	_	_	_	_
2-3	28-37	vitamin-D	abstract[3]	new[3]	coref	2-6[4_3]
2-4	38-48	deficiency	abstract[3]	new[3]	_	_
2-5	49-52	are	_	_	_	_
2-6	53-56	two	abstract[4]	giv[4]	coref	4-10[16_4]
2-7	57-62	major	abstract[4]	giv[4]	_	_
2-8	63-69	global	abstract[4]	giv[4]	_	_
2-9	70-76	public	abstract[4]	giv[4]	_	_
2-10	77-83	health	abstract[4]	giv[4]	_	_
2-11	84-92	concerns	abstract[4]	giv[4]	_	_
2-12	93-97	that	_	_	_	_
2-13	98-104	affect	_	_	_	_
2-14	105-109	over	_	_	_	_
2-15	110-119	one-third	quantity[5]	new[5]	_	_
2-16	120-122	of	quantity[5]	new[5]	_	_
2-17	123-126	the	quantity[5]|person[6]	new[5]|new[6]	coref	22-25[190_6]
2-18	127-137	population	quantity[5]|person[6]	new[5]|new[6]	_	_
2-19	138-139	.	_	_	_	_

#Text=A body mass index of more than 30 kg/m2 is associated with lower serum vitamin-D levels compared with non-obese individuals .
3-1	140-141	A	abstract[9]	new[9]	coref	15-16[119_9]
3-2	142-146	body	object|abstract[9]	new|new[9]	coref	18-6[144_0]
3-3	147-151	mass	quantity|abstract[9]	new|new[9]	_	_
3-4	152-157	index	abstract[9]	new[9]	_	_
3-5	158-160	of	abstract[9]	new[9]	_	_
3-6	161-165	more	abstract[9]|quantity[10]	new[9]|new[10]	_	_
3-7	166-170	than	abstract[9]|quantity[10]	new[9]|new[10]	_	_
3-8	171-173	30	abstract[9]|quantity[10]	new[9]|new[10]	_	_
3-9	174-179	kg/m2	abstract[9]|quantity[10]	new[9]|new[10]	_	_
3-10	180-182	is	_	_	_	_
3-11	183-193	associated	_	_	_	_
3-12	194-198	with	_	_	_	_
3-13	199-204	lower	abstract[12]	new[12]	coref	5-24[26_12]
3-14	205-210	serum	abstract|abstract[12]	new|new[12]	coref	13-11
3-15	211-220	vitamin-D	abstract[12]	new[12]	_	_
3-16	221-227	levels	abstract[12]	new[12]	_	_
3-17	228-236	compared	_	_	_	_
3-18	237-241	with	_	_	_	_
3-19	242-251	non-obese	person[13]	new[13]	coref	5-18[25_13]
3-20	252-263	individuals	person[13]	new[13]	_	_
3-21	264-265	.	_	_	_	_

#Text=Several mechanisms that contribute to the high incidence of vitamin-D deficiency in obese people were suggested .
4-1	266-273	Several	abstract[14]	new[14]	coref	7-35[56_14]
4-2	274-284	mechanisms	abstract[14]	new[14]	_	_
4-3	285-289	that	_	_	_	_
4-4	290-300	contribute	_	_	_	_
4-5	301-303	to	_	_	_	_
4-6	304-307	the	abstract[15]	new[15]	_	_
4-7	308-312	high	abstract[15]	new[15]	_	_
4-8	313-322	incidence	abstract[15]	new[15]	_	_
4-9	323-325	of	abstract[15]	new[15]	_	_
4-10	326-335	vitamin-D	abstract[15]|abstract[16]	new[15]|giv[16]	coref	7-3[43_16]
4-11	336-346	deficiency	abstract[15]|abstract[16]	new[15]|giv[16]	_	_
4-12	347-349	in	abstract[15]|abstract[16]	new[15]|giv[16]	_	_
4-13	350-355	obese	abstract[15]|abstract[16]|person[17]	new[15]|giv[16]|new[17]	_	_
4-14	356-362	people	abstract[15]|abstract[16]|person[17]	new[15]|giv[16]|new[17]	_	_
4-15	363-367	were	_	_	_	_
4-16	368-377	suggested	_	_	_	_
4-17	378-379	.	_	_	_	_

#Text=Ultraviolet radiation from sunlight exposure is required for cutaneous production of vitamin D. It was proposed that obese individuals , overall , have suboptimal levels of vitamin D because they tend to participate in fewer outdoor activities and , accordingly , have less exposure to sunlight .
5-1	380-391	Ultraviolet	abstract[18]	new[18]	_	_
5-2	392-401	radiation	abstract[18]	new[18]	_	_
5-3	402-406	from	abstract[18]	new[18]	_	_
5-4	407-415	sunlight	abstract[18]|substance|abstract[20]	new[18]|new|new[20]	coref|coref	5-43[31_20]|5-43[31_20]
5-5	416-424	exposure	abstract[18]|abstract[20]	new[18]|new[20]	_	_
5-6	425-427	is	_	_	_	_
5-7	428-436	required	_	_	_	_
5-8	437-440	for	_	_	_	_
5-9	441-450	cutaneous	abstract[21]	new[21]	ana	5-14[0_21]
5-10	451-461	production	abstract[21]	new[21]	_	_
5-11	462-464	of	abstract[21]	new[21]	_	_
5-12	465-472	vitamin	abstract[21]|substance	new[21]|new	coref	5-27
5-13	473-475	D.	abstract[21]|person	new[21]|new	coref	7-17
5-14	476-478	It	abstract	giv	coref	21-26[182_0]
5-15	479-482	was	_	_	_	_
5-16	483-491	proposed	_	_	_	_
5-17	492-496	that	_	_	_	_
5-18	497-502	obese	person[25]	giv[25]	ana	5-30[0_25]
5-19	503-514	individuals	person[25]	giv[25]	_	_
5-20	515-516	,	person[25]	giv[25]	_	_
5-21	517-524	overall	person[25]	giv[25]	_	_
5-22	525-526	,	_	_	_	_
5-23	527-531	have	_	_	_	_
5-24	532-542	suboptimal	abstract[26]	giv[26]	coref	13-10[94_26]
5-25	543-549	levels	abstract[26]	giv[26]	_	_
5-26	550-552	of	abstract[26]	giv[26]	_	_
5-27	553-560	vitamin	abstract[26]|substance|person[28]	giv[26]|giv|new[28]	coref|coref|coref|coref	6-1[32_0]|6-17[37_28]|6-1[32_0]|6-17[37_28]
5-28	561-562	D	abstract[26]|person[28]	giv[26]|new[28]	_	_
5-29	563-570	because	_	_	_	_
5-30	571-575	they	person	giv	coref	6-20[38_0]
5-31	576-580	tend	_	_	_	_
5-32	581-583	to	_	_	_	_
5-33	584-595	participate	_	_	_	_
5-34	596-598	in	_	_	_	_
5-35	599-604	fewer	abstract[30]	new[30]	_	_
5-36	605-612	outdoor	abstract[30]	new[30]	_	_
5-37	613-623	activities	abstract[30]	new[30]	_	_
5-38	624-627	and	_	_	_	_
5-39	628-629	,	_	_	_	_
5-40	630-641	accordingly	_	_	_	_
5-41	642-643	,	_	_	_	_
5-42	644-648	have	_	_	_	_
5-43	649-653	less	abstract[31]	giv[31]	ana	6-9[0_31]
5-44	654-662	exposure	abstract[31]	giv[31]	_	_
5-45	663-665	to	abstract[31]	giv[31]	_	_
5-46	666-674	sunlight	abstract[31]	giv[31]	_	_
5-47	675-676	.	_	_	_	_

#Text=Vitamin D is a lipid-soluble vitamin , and it is thought that the lower bioavailability of vitamin D in obese individuals , compared to lean individuals , is due to vitamin-D sequestration within the adipose tissues .
6-1	677-684	Vitamin	substance[32]	giv[32]	coref	6-4[33_32]
6-2	685-686	D	substance[32]	giv[32]	_	_
6-3	687-689	is	_	_	_	_
6-4	690-691	a	substance[33]	giv[33]	coref	6-17[0_33]
6-5	692-705	lipid-soluble	substance[33]	giv[33]	_	_
6-6	706-713	vitamin	substance[33]	giv[33]	_	_
6-7	714-715	,	_	_	_	_
6-8	716-719	and	_	_	_	_
6-9	720-722	it	abstract	giv	_	_
6-10	723-725	is	_	_	_	_
6-11	726-733	thought	_	_	_	_
6-12	734-738	that	_	_	_	_
6-13	739-742	the	substance[35]	new[35]	_	_
6-14	743-748	lower	substance[35]	new[35]	_	_
6-15	749-764	bioavailability	substance[35]	new[35]	_	_
6-16	765-767	of	substance[35]	new[35]	_	_
6-17	768-775	vitamin	substance[35]|substance|person[37]	new[35]|giv|giv[37]	coref|coref|coref|coref	7-16|9-7[0_37]|7-16|9-7[0_37]
6-18	776-777	D	substance[35]|person[37]	new[35]|giv[37]	_	_
6-19	778-780	in	substance[35]	new[35]	_	_
6-20	781-786	obese	substance[35]|person[38]	new[35]|giv[38]	coref	6-26[0_38]
6-21	787-798	individuals	substance[35]|person[38]	new[35]|giv[38]	_	_
6-22	799-800	,	_	_	_	_
6-23	801-809	compared	_	_	_	_
6-24	810-812	to	_	_	_	_
6-25	813-817	lean	_	_	_	_
6-26	818-829	individuals	person	giv	coref	25-17[223_0]
6-27	830-831	,	_	_	_	_
6-28	832-834	is	_	_	_	_
6-29	835-838	due	_	_	_	_
6-30	839-841	to	_	_	_	_
6-31	842-851	vitamin-D	_	_	_	_
6-32	852-865	sequestration	substance	new	_	_
6-33	866-872	within	_	_	_	_
6-34	873-876	the	object[42]	new[42]	coref	18-14[0_42]
6-35	877-884	adipose	abstract|object[42]	new|new[42]	coref	23-27
6-36	885-892	tissues	object[42]	new[42]	_	_
6-37	893-894	.	_	_	_	_

#Text=Lastly , vitamin-D deficiency may also be due to inadequate dietary intake or malabsorption of vitamin D. Obesity is a well-established risk factor for the development of cardiovascular disease ( CVD ) , and several mechanisms may contribute to this link .
7-1	895-901	Lastly	_	_	_	_
7-2	902-903	,	_	_	_	_
7-3	904-913	vitamin-D	abstract[43]	giv[43]	coref	8-6[59_43]
7-4	914-924	deficiency	abstract[43]	giv[43]	_	_
7-5	925-928	may	_	_	_	_
7-6	929-933	also	_	_	_	_
7-7	934-936	be	_	_	_	_
7-8	937-940	due	_	_	_	_
7-9	941-943	to	_	_	_	_
7-10	944-954	inadequate	event[45]	new[45]	coref	14-9[100_45]
7-11	955-962	dietary	abstract|event[45]	new|new[45]	_	_
7-12	963-969	intake	event[45]	new[45]	_	_
7-13	970-972	or	_	_	_	_
7-14	973-986	malabsorption	abstract[46]	new[46]	_	_
7-15	987-989	of	abstract[46]	new[46]	_	_
7-16	990-997	vitamin	abstract[46]|substance|abstract[49]	new[46]|giv|giv[49]	coref|coref|coref|coref	9-6|26-15[0_49]|9-6|26-15[0_49]
7-17	998-1000	D.	abstract[46]|person|abstract[49]	new[46]|giv|giv[49]	_	_
7-18	1001-1008	Obesity	abstract[46]|abstract[49]	new[46]|giv[49]	_	_
7-19	1009-1011	is	_	_	_	_
7-20	1012-1013	a	abstract[51]	new[51]	_	_
7-21	1014-1030	well-established	abstract[51]	new[51]	_	_
7-22	1031-1035	risk	abstract|abstract[51]	new|new[51]	coref	8-14
7-23	1036-1042	factor	abstract[51]	new[51]	_	_
7-24	1043-1046	for	abstract[51]	new[51]	_	_
7-25	1047-1050	the	abstract[51]|abstract[52]	new[51]|new[52]	_	_
7-26	1051-1062	development	abstract[51]|abstract[52]	new[51]|new[52]	_	_
7-27	1063-1065	of	abstract[51]|abstract[52]	new[51]|new[52]	_	_
7-28	1066-1080	cardiovascular	abstract[51]|abstract[52]|abstract|abstract[54]	new[51]|new[52]|new|new[54]	appos|coref|appos|coref	7-31[0_54]|8-9[60_0]|7-31[0_54]|8-9[60_0]
7-29	1081-1088	disease	abstract[51]|abstract[52]|abstract[54]	new[51]|new[52]|new[54]	_	_
7-30	1089-1090	(	_	_	_	_
7-31	1091-1094	CVD	abstract	giv	coref	11-17
7-32	1095-1096	)	_	_	_	_
7-33	1097-1098	,	_	_	_	_
7-34	1099-1102	and	_	_	_	_
7-35	1103-1110	several	abstract[56]	giv[56]	_	_
7-36	1111-1121	mechanisms	abstract[56]	giv[56]	_	_
7-37	1122-1125	may	_	_	_	_
7-38	1126-1136	contribute	_	_	_	_
7-39	1137-1139	to	_	_	_	_
7-40	1140-1144	this	abstract[57]	new[57]	_	_
7-41	1145-1149	link	abstract[57]	new[57]	_	_
7-42	1150-1151	.	_	_	_	_

#Text=However , a role of vitamin-D deficiency in obesity-associated cardiovascular ( CV ) risk is yet to be established .
8-1	1152-1159	However	_	_	_	_
8-2	1160-1161	,	_	_	_	_
8-3	1162-1163	a	abstract[58]	new[58]	_	_
8-4	1164-1168	role	abstract[58]	new[58]	_	_
8-5	1169-1171	of	abstract[58]	new[58]	_	_
8-6	1172-1181	vitamin-D	abstract[58]|abstract[59]	new[58]|giv[59]	coref	9-6[67_59]
8-7	1182-1192	deficiency	abstract[58]|abstract[59]	new[58]|giv[59]	_	_
8-8	1193-1195	in	abstract[58]|abstract[59]	new[58]|giv[59]	_	_
8-9	1196-1214	obesity-associated	abstract[58]|abstract[59]|abstract[60]	new[58]|giv[59]|giv[60]	_	_
8-10	1215-1229	cardiovascular	abstract[58]|abstract[59]|abstract[60]	new[58]|giv[59]|giv[60]	_	_
8-11	1230-1231	(	_	_	_	_
8-12	1232-1234	CV	person	new	_	_
8-13	1235-1236	)	_	_	_	_
8-14	1237-1241	risk	abstract	giv	coref	12-6[87_0]
8-15	1242-1244	is	_	_	_	_
8-16	1245-1248	yet	_	_	_	_
8-17	1249-1251	to	_	_	_	_
8-18	1252-1254	be	_	_	_	_
8-19	1255-1266	established	_	_	_	_
8-20	1267-1268	.	_	_	_	_

#Text=Epidemiological data reported associations between vitamin D deficiency and left ventricular hypertrophy , hypertension , increased arterial stiffness , and endothelial dysfunction .
9-1	1269-1284	Epidemiological	abstract[63]	new[63]	_	_
9-2	1285-1289	data	abstract[63]	new[63]	_	_
9-3	1290-1298	reported	_	_	_	_
9-4	1299-1311	associations	abstract[64]	new[64]	coref	10-5[74_64]
9-5	1312-1319	between	abstract[64]	new[64]	_	_
9-6	1320-1327	vitamin	abstract[64]|substance|abstract[67]	new[64]|giv|giv[67]	coref|coref|coref|coref	11-11|11-25[83_67]|11-11|11-25[83_67]
9-7	1328-1329	D	abstract[64]|person|abstract[67]	new[64]|giv|giv[67]	coref	11-12
9-8	1330-1340	deficiency	abstract[64]|abstract[67]	new[64]|giv[67]	_	_
9-9	1341-1344	and	_	_	_	_
9-10	1345-1349	left	_	_	_	_
9-11	1350-1361	ventricular	abstract[68]	new[68]	_	_
9-12	1362-1373	hypertrophy	abstract[68]	new[68]	_	_
9-13	1374-1375	,	_	_	_	_
9-14	1376-1388	hypertension	abstract	new	coref	11-28
9-15	1389-1390	,	_	_	_	_
9-16	1391-1400	increased	abstract[70]	new[70]	coref	15-22[121_70]
9-17	1401-1409	arterial	abstract[70]	new[70]	_	_
9-18	1410-1419	stiffness	abstract[70]	new[70]	_	_
9-19	1420-1421	,	_	_	_	_
9-20	1422-1425	and	_	_	_	_
9-21	1426-1437	endothelial	abstract|abstract[72]	new|new[72]	coref|coref|coref|coref	18-25|21-21[180_72]|18-25|21-21[180_72]
9-22	1438-1449	dysfunction	abstract[72]	new[72]	_	_
9-23	1450-1451	.	_	_	_	_

#Text=The pathophysiological underpinnings of these associations remain mostly unexplained .
10-1	1452-1455	The	abstract[73]	new[73]	_	_
10-2	1456-1474	pathophysiological	abstract[73]	new[73]	_	_
10-3	1475-1488	underpinnings	abstract[73]	new[73]	_	_
10-4	1489-1491	of	abstract[73]	new[73]	_	_
10-5	1492-1497	these	abstract[73]|abstract[74]	new[73]|giv[74]	_	_
10-6	1498-1510	associations	abstract[73]|abstract[74]	new[73]|giv[74]	_	_
10-7	1511-1517	remain	_	_	_	_
10-8	1518-1524	mostly	_	_	_	_
10-9	1525-1536	unexplained	_	_	_	_
10-10	1537-1538	.	_	_	_	_

#Text=The most reliable and convincing evidence for the involvement of vitamin D in the pathogenesis of CVD comes from studies demonstrating an association between vitamin-D deficiency and hypertension .
11-1	1539-1542	The	abstract[75]	new[75]	coref	22-2[183_75]
11-2	1543-1547	most	abstract[75]	new[75]	_	_
11-3	1548-1556	reliable	abstract[75]	new[75]	_	_
11-4	1557-1560	and	abstract[75]	new[75]	_	_
11-5	1561-1571	convincing	abstract[75]	new[75]	_	_
11-6	1572-1580	evidence	abstract[75]	new[75]	_	_
11-7	1581-1584	for	abstract[75]	new[75]	_	_
11-8	1585-1588	the	abstract[75]|abstract[76]	new[75]|new[76]	_	_
11-9	1589-1600	involvement	abstract[75]|abstract[76]	new[75]|new[76]	_	_
11-10	1601-1603	of	abstract[75]|abstract[76]	new[75]|new[76]	_	_
11-11	1604-1611	vitamin	abstract[75]|abstract[76]|substance	new[75]|new[76]|giv	coref	16-16[129_0]
11-12	1612-1613	D	abstract[75]|abstract[76]|person	new[75]|new[76]|giv	coref	17-13[135_0]
11-13	1614-1616	in	abstract[75]|abstract[76]	new[75]|new[76]	_	_
11-14	1617-1620	the	abstract[75]|abstract[76]|abstract[79]	new[75]|new[76]|new[79]	_	_
11-15	1621-1633	pathogenesis	abstract[75]|abstract[76]|abstract[79]	new[75]|new[76]|new[79]	_	_
11-16	1634-1636	of	abstract[75]|abstract[76]|abstract[79]	new[75]|new[76]|new[79]	_	_
11-17	1637-1640	CVD	abstract[75]|abstract[76]|abstract[79]|event	new[75]|new[76]|new[79]|giv	coref	21-17
11-18	1641-1646	comes	_	_	_	_
11-19	1647-1651	from	_	_	_	_
11-20	1652-1659	studies	event	new	coref	19-1[153_0]
11-21	1660-1673	demonstrating	_	_	_	_
11-22	1674-1676	an	abstract[82]	new[82]	coref	13-3[92_82]
11-23	1677-1688	association	abstract[82]	new[82]	_	_
11-24	1689-1696	between	abstract[82]	new[82]	_	_
11-25	1697-1706	vitamin-D	abstract[82]|abstract[83]|abstract[84]	new[82]|giv[83]|new[84]	coref|coref|coref|coref	12-1[86_83]|21-14[177_84]|12-1[86_83]|21-14[177_84]
11-26	1707-1717	deficiency	abstract[82]|abstract[83]|abstract[84]	new[82]|giv[83]|new[84]	_	_
11-27	1718-1721	and	abstract[82]|abstract[84]	new[82]|new[84]	_	_
11-28	1722-1734	hypertension	abstract[82]|abstract[84]|abstract	new[82]|new[84]|giv	coref	12-18
11-29	1735-1736	.	_	_	_	_

#Text=Vitamin-D deficiency is associated with a higher risk for preeclampsia , a condition that is characterized by hypertension .
12-1	1737-1746	Vitamin-D	abstract[86]	giv[86]	coref	21-14[176_86]
12-2	1747-1757	deficiency	abstract[86]	giv[86]	_	_
12-3	1758-1760	is	_	_	_	_
12-4	1761-1771	associated	_	_	_	_
12-5	1772-1776	with	_	_	_	_
12-6	1777-1778	a	abstract[87]	giv[87]	_	_
12-7	1779-1785	higher	abstract[87]	giv[87]	_	_
12-8	1786-1790	risk	abstract[87]	giv[87]	_	_
12-9	1791-1794	for	abstract[87]	giv[87]	_	_
12-10	1795-1807	preeclampsia	abstract[87]|abstract	giv[87]|new	appos	12-12[89_0]
12-11	1808-1809	,	_	_	_	_
12-12	1810-1811	a	abstract[89]	giv[89]	_	_
12-13	1812-1821	condition	abstract[89]	giv[89]	_	_
12-14	1822-1826	that	_	_	_	_
12-15	1827-1829	is	_	_	_	_
12-16	1830-1843	characterized	_	_	_	_
12-17	1844-1846	by	_	_	_	_
12-18	1847-1859	hypertension	abstract	giv	coref	15-30
12-19	1860-1861	.	_	_	_	_

#Text=Also , a significant inverse association was reported between vitamin-D serum levels and arterial blood pressure in the elderly .
13-1	1862-1866	Also	_	_	_	_
13-2	1867-1868	,	_	_	_	_
13-3	1869-1870	a	abstract[92]	giv[92]	coref	21-11[175_92]
13-4	1871-1882	significant	abstract[92]	giv[92]	_	_
13-5	1883-1890	inverse	place|abstract[92]	new|giv[92]	_	_
13-6	1891-1902	association	abstract[92]	giv[92]	_	_
13-7	1903-1906	was	_	_	_	_
13-8	1907-1915	reported	_	_	_	_
13-9	1916-1923	between	_	_	_	_
13-10	1924-1933	vitamin-D	abstract[94]	giv[94]	_	_
13-11	1934-1939	serum	substance|abstract[94]	giv|giv[94]	_	_
13-12	1940-1946	levels	abstract[94]	giv[94]	_	_
13-13	1947-1950	and	abstract[94]	giv[94]	_	_
13-14	1951-1959	arterial	abstract[94]|abstract[96]	giv[94]|new[96]	coref	14-35[111_96]
13-15	1960-1965	blood	abstract[94]|substance|abstract[96]	giv[94]|new|new[96]	coref	14-31
13-16	1966-1974	pressure	abstract[94]|abstract[96]	giv[94]|new[96]	_	_
13-17	1975-1977	in	abstract[94]|abstract[96]	giv[94]|new[96]	_	_
13-18	1978-1981	the	abstract[94]|abstract[96]	giv[94]|new[96]	_	_
13-19	1982-1989	elderly	abstract[94]|abstract[96]	giv[94]|new[96]	_	_
13-20	1990-1991	.	_	_	_	_

#Text=An interventional study demonstrated that one month of vitamin-D intake ( 1,5000 IU/day ) reduced tissue sensitivity to the stimulation of the renin – angiotensin system manifested by improved renal blood flow and reduced mean arterial pressure during an infusion of angiotensin II .
14-1	1992-1994	An	abstract[97]	new[97]	coref	20-1[165_97]
14-2	1995-2009	interventional	abstract[97]	new[97]	_	_
14-3	2010-2015	study	abstract[97]	new[97]	_	_
14-4	2016-2028	demonstrated	_	_	_	_
14-5	2029-2033	that	time[98]	new[98]	_	_
14-6	2034-2037	one	time[98]	new[98]	_	_
14-7	2038-2043	month	time[98]	new[98]	_	_
14-8	2044-2046	of	time[98]	new[98]	_	_
14-9	2047-2056	vitamin-D	time[98]|substance|event[100]	new[98]|new|giv[100]	coref|coref	15-1[114_100]|15-1[114_100]
14-10	2057-2063	intake	time[98]|event[100]	new[98]|giv[100]	_	_
14-11	2064-2065	(	_	_	_	_
14-12	2066-2072	1,5000	quantity[101]	new[101]	_	_
14-13	2073-2079	IU/day	quantity[101]	new[101]	_	_
14-14	2080-2081	)	_	_	_	_
14-15	2082-2089	reduced	_	_	_	_
14-16	2090-2096	tissue	object|abstract[103]	new|new[103]	coref|coref	23-26[202_0]|23-26[202_0]
14-17	2097-2108	sensitivity	abstract[103]	new[103]	_	_
14-18	2109-2111	to	abstract[103]	new[103]	_	_
14-19	2112-2115	the	abstract[103]|abstract[104]	new[103]|new[104]	_	_
14-20	2116-2127	stimulation	abstract[103]|abstract[104]	new[103]|new[104]	_	_
14-21	2128-2130	of	abstract[103]|abstract[104]	new[103]|new[104]	_	_
14-22	2131-2134	the	abstract[103]|abstract[104]|substance[105]	new[103]|new[104]|new[105]	coref	19-22[161_105]
14-23	2135-2140	renin	abstract[103]|abstract[104]|substance[105]	new[103]|new[104]|new[105]	_	_
14-24	2141-2142	–	_	_	_	_
14-25	2143-2154	angiotensin	person|abstract[107]	new|new[107]	coref|coref|coref|coref	14-42[113_0]|19-27[164_107]|14-42[113_0]|19-27[164_107]
14-26	2155-2161	system	abstract[107]	new[107]	_	_
14-27	2162-2172	manifested	_	_	_	_
14-28	2173-2175	by	_	_	_	_
14-29	2176-2184	improved	abstract[110]	new[110]	_	_
14-30	2185-2190	renal	abstract|abstract[110]	new|new[110]	_	_
14-31	2191-2196	blood	substance|abstract[110]	giv|new[110]	coref	19-17
14-32	2197-2201	flow	abstract[110]	new[110]	_	_
14-33	2202-2205	and	_	_	_	_
14-34	2206-2213	reduced	_	_	_	_
14-35	2214-2218	mean	abstract[111]	giv[111]	coref	19-16[160_111]
14-36	2219-2227	arterial	abstract[111]	giv[111]	_	_
14-37	2228-2236	pressure	abstract[111]	giv[111]	_	_
14-38	2237-2243	during	_	_	_	_
14-39	2244-2246	an	event[112]	new[112]	_	_
14-40	2247-2255	infusion	event[112]	new[112]	_	_
14-41	2256-2258	of	event[112]	new[112]	_	_
14-42	2259-2270	angiotensin	event[112]|person[113]	new[112]|giv[113]	coref	19-25[0_113]
14-43	2271-2273	II	event[112]|person[113]	new[112]|giv[113]	_	_
14-44	2274-2275	.	_	_	_	_

#Text=Moreover , vitamin-D intake ( 2000 IU/day ) for 14 days in healthy adults reduced augmentation index , a measure of arterial stiffness that contributes to the development of hypertension .
15-1	2276-2284	Moreover	event[114]	giv[114]	_	_
15-2	2285-2286	,	event[114]	giv[114]	_	_
15-3	2287-2296	vitamin-D	event[114]	giv[114]	_	_
15-4	2297-2303	intake	event[114]	giv[114]	_	_
15-5	2304-2305	(	_	_	_	_
15-6	2306-2310	2000	quantity[115]	new[115]	_	_
15-7	2311-2317	IU/day	quantity[115]	new[115]	_	_
15-8	2318-2319	)	_	_	_	_
15-9	2320-2323	for	_	_	_	_
15-10	2324-2326	14	time[116]	new[116]	_	_
15-11	2327-2331	days	time[116]	new[116]	_	_
15-12	2332-2334	in	time[116]	new[116]	_	_
15-13	2335-2342	healthy	time[116]|person[117]	new[116]|new[117]	coref	23-33[204_117]
15-14	2343-2349	adults	time[116]|person[117]	new[116]|new[117]	_	_
15-15	2350-2357	reduced	_	_	_	_
15-16	2358-2370	augmentation	abstract|abstract[119]	new|giv[119]	_	_
15-17	2371-2376	index	abstract[119]	giv[119]	_	_
15-18	2377-2378	,	_	_	_	_
15-19	2379-2380	a	abstract[120]	new[120]	_	_
15-20	2381-2388	measure	abstract[120]	new[120]	_	_
15-21	2389-2391	of	abstract[120]	new[120]	_	_
15-22	2392-2400	arterial	abstract[120]|abstract[121]	new[120]|giv[121]	coref	19-9[156_121]
15-23	2401-2410	stiffness	abstract[120]|abstract[121]	new[120]|giv[121]	_	_
15-24	2411-2415	that	_	_	_	_
15-25	2416-2427	contributes	_	_	_	_
15-26	2428-2430	to	_	_	_	_
15-27	2431-2434	the	event[122]	new[122]	_	_
15-28	2435-2446	development	event[122]	new[122]	_	_
15-29	2447-2449	of	event[122]	new[122]	_	_
15-30	2450-2462	hypertension	event[122]|abstract	new[122]|giv	_	_
15-31	2463-2464	.	_	_	_	_

#Text=The discovery of vitamin-D receptor ( VDR ) widened the scope of biological effects that vitamin D plays in human health .
16-1	2465-2468	The	event[124]	new[124]	_	_
16-2	2469-2478	discovery	event[124]	new[124]	_	_
16-3	2479-2481	of	event[124]	new[124]	_	_
16-4	2482-2491	vitamin-D	event[124]|substance[125]	new[124]|new[125]	_	_
16-5	2492-2500	receptor	event[124]|substance[125]	new[124]|new[125]	_	_
16-6	2501-2502	(	_	_	_	_
16-7	2503-2506	VDR	abstract	new	coref	17-1
16-8	2507-2508	)	_	_	_	_
16-9	2509-2516	widened	_	_	_	_
16-10	2517-2520	the	abstract[127]	new[127]	_	_
16-11	2521-2526	scope	abstract[127]	new[127]	_	_
16-12	2527-2529	of	abstract[127]	new[127]	_	_
16-13	2530-2540	biological	abstract[127]|abstract[128]	new[127]|new[128]	coref	23-10[195_128]
16-14	2541-2548	effects	abstract[127]|abstract[128]	new[127]|new[128]	_	_
16-15	2549-2553	that	_	_	_	_
16-16	2554-2561	vitamin	substance[129]	giv[129]	coref	17-13[0_129]
16-17	2562-2563	D	substance[129]	giv[129]	_	_
16-18	2564-2569	plays	_	_	_	_
16-19	2570-2572	in	_	_	_	_
16-20	2573-2578	human	abstract[130]	new[130]	_	_
16-21	2579-2585	health	abstract[130]	new[130]	_	_
16-22	2586-2587	.	_	_	_	_

#Text=VDR is a transcription factor that enters the nucleus upon binding to vitamin D , where it attaches to specific DNA regions and activates the transcription of a myriad of genes that coordinate several biological responses .
17-1	2588-2591	VDR	abstract	giv	coref	17-3[132_0]
17-2	2592-2594	is	_	_	_	_
17-3	2595-2596	a	abstract[132]	giv[132]	coref	18-1[0_132]
17-4	2597-2610	transcription	abstract[132]	giv[132]	_	_
17-5	2611-2617	factor	abstract[132]	giv[132]	_	_
17-6	2618-2622	that	_	_	_	_
17-7	2623-2629	enters	_	_	_	_
17-8	2630-2633	the	place[133]	new[133]	_	_
17-9	2634-2641	nucleus	place[133]	new[133]	_	_
17-10	2642-2646	upon	_	_	_	_
17-11	2647-2654	binding	_	_	_	_
17-12	2655-2657	to	_	_	_	_
17-13	2658-2665	vitamin	substance|substance[135]	giv|giv[135]	ana|coref|ana|coref	17-17[0_135]|22-9[185_0]|17-17[0_135]|22-9[185_0]
17-14	2666-2667	D	substance[135]	giv[135]	_	_
17-15	2668-2669	,	_	_	_	_
17-16	2670-2675	where	_	_	_	_
17-17	2676-2678	it	substance	giv	coref	23-13[197_0]
17-18	2679-2687	attaches	_	_	_	_
17-19	2688-2690	to	_	_	_	_
17-20	2691-2699	specific	place[138]	new[138]	_	_
17-21	2700-2703	DNA	substance|place[138]	new|new[138]	_	_
17-22	2704-2711	regions	place[138]	new[138]	_	_
17-23	2712-2715	and	_	_	_	_
17-24	2716-2725	activates	_	_	_	_
17-25	2726-2729	the	event[139]	new[139]	_	_
17-26	2730-2743	transcription	event[139]	new[139]	_	_
17-27	2744-2746	of	event[139]	new[139]	_	_
17-28	2747-2748	a	event[139]|abstract[140]	new[139]|new[140]	_	_
17-29	2749-2755	myriad	event[139]|abstract[140]	new[139]|new[140]	_	_
17-30	2756-2758	of	event[139]|abstract[140]	new[139]|new[140]	_	_
17-31	2759-2764	genes	event[139]|abstract[140]|abstract	new[139]|new[140]|new	_	_
17-32	2765-2769	that	_	_	_	_
17-33	2770-2780	coordinate	_	_	_	_
17-34	2781-2788	several	event[142]	new[142]	_	_
17-35	2789-2799	biological	event[142]	new[142]	_	_
17-36	2800-2809	responses	event[142]	new[142]	_	_
17-37	2810-2811	.	_	_	_	_

#Text=VDR is widely expressed throughout the human body in almost all cells and tissues , including vascular smooth muscle cells , cardiomyocytes , and endothelial cells .
18-1	2812-2815	VDR	abstract	giv	coref	19-7
18-2	2816-2818	is	_	_	_	_
18-3	2819-2825	widely	_	_	_	_
18-4	2826-2835	expressed	_	_	_	_
18-5	2836-2846	throughout	_	_	_	_
18-6	2847-2850	the	object[144]	giv[144]	_	_
18-7	2851-2856	human	object[144]	giv[144]	_	_
18-8	2857-2861	body	object[144]	giv[144]	_	_
18-9	2862-2864	in	object[144]	giv[144]	_	_
18-10	2865-2871	almost	object[144]|object[145]	giv[144]|new[145]	_	_
18-11	2872-2875	all	object[144]|object[145]	giv[144]|new[145]	_	_
18-12	2876-2881	cells	object[144]|object[145]	giv[144]|new[145]	_	_
18-13	2882-2885	and	object[144]	giv[144]	_	_
18-14	2886-2893	tissues	object[144]|object	giv[144]|giv	_	_
18-15	2894-2895	,	object[144]	giv[144]	_	_
18-16	2896-2905	including	object[144]	giv[144]	_	_
18-17	2906-2914	vascular	object[144]|object[148]	giv[144]|new[148]	_	_
18-18	2915-2921	smooth	object[144]|object[148]	giv[144]|new[148]	_	_
18-19	2922-2928	muscle	object[144]|object|object[148]	giv[144]|new|new[148]	_	_
18-20	2929-2934	cells	object[144]|object[148]	giv[144]|new[148]	_	_
18-21	2935-2936	,	object[144]	giv[144]	_	_
18-22	2937-2951	cardiomyocytes	object[144]|object	giv[144]|new	_	_
18-23	2952-2953	,	object[144]	giv[144]	_	_
18-24	2954-2957	and	object[144]	giv[144]	_	_
18-25	2958-2969	endothelial	object[144]|object|object[151]	giv[144]|giv|new[151]	coref|coref	21-21|21-21
18-26	2970-2975	cells	object[144]|object[151]	giv[144]|new[151]	_	_
18-27	2976-2977	.	_	_	_	_

#Text=Animal studies found that loss of VDR signaling increased arterial stiffness and elevated systolic and diastolic blood pressure , independent of the renin – angiotensin – aldosterone system .
19-1	2978-2984	Animal	person|event[153]	new|giv[153]	coref|coref	21-1[173_153]|21-1[173_153]
19-2	2985-2992	studies	event[153]	giv[153]	_	_
19-3	2993-2998	found	_	_	_	_
19-4	2999-3003	that	abstract[154]	new[154]	coref	22-34[192_154]
19-5	3004-3008	loss	abstract[154]	new[154]	_	_
19-6	3009-3011	of	abstract[154]	new[154]	_	_
19-7	3012-3015	VDR	abstract[154]|abstract	new[154]|giv	coref	20-5
19-8	3016-3025	signaling	_	_	_	_
19-9	3026-3035	increased	abstract[156]	giv[156]	coref	20-10[169_156]
19-10	3036-3044	arterial	abstract[156]	giv[156]	_	_
19-11	3045-3054	stiffness	abstract[156]	giv[156]	_	_
19-12	3055-3058	and	_	_	_	_
19-13	3059-3067	elevated	abstract[157]	new[157]	_	_
19-14	3068-3076	systolic	abstract[157]	new[157]	_	_
19-15	3077-3080	and	_	_	_	_
19-16	3081-3090	diastolic	person|abstract[160]	new|giv[160]	_	_
19-17	3091-3096	blood	substance|abstract[160]	giv|giv[160]	_	_
19-18	3097-3105	pressure	abstract[160]	giv[160]	_	_
19-19	3106-3107	,	abstract[160]	giv[160]	_	_
19-20	3108-3119	independent	abstract[160]	giv[160]	_	_
19-21	3120-3122	of	_	_	_	_
19-22	3123-3126	the	substance[161]	giv[161]	_	_
19-23	3127-3132	renin	substance[161]	giv[161]	_	_
19-24	3133-3134	–	_	_	_	_
19-25	3135-3146	angiotensin	person	giv	_	_
19-26	3147-3148	–	_	_	_	_
19-27	3149-3160	aldosterone	object|abstract[164]	new|giv[164]	coref|coref	27-2[230_164]|27-2[230_164]
19-28	3161-3167	system	abstract[164]	giv[164]	_	_
19-29	3168-3169	.	_	_	_	_

#Text=Another study found that VDR knockout mice have increased arterial stiffness through decreased bioavailability of nitric oxide ( NO ) .
20-1	3170-3177	Another	abstract[165]	giv[165]	coref	23-4[194_165]
20-2	3178-3183	study	abstract[165]	giv[165]	_	_
20-3	3184-3189	found	_	_	_	_
20-4	3190-3194	that	_	_	_	_
20-5	3195-3198	VDR	abstract|abstract[168]	giv|new[168]	_	_
20-6	3199-3207	knockout	event|abstract[168]	new|new[168]	_	_
20-7	3208-3212	mice	abstract[168]	new[168]	_	_
20-8	3213-3217	have	_	_	_	_
20-9	3218-3227	increased	_	_	_	_
20-10	3228-3236	arterial	abstract[169]	giv[169]	_	_
20-11	3237-3246	stiffness	abstract[169]	giv[169]	_	_
20-12	3247-3254	through	_	_	_	_
20-13	3255-3264	decreased	substance[170]	new[170]	_	_
20-14	3265-3280	bioavailability	substance[170]	new[170]	_	_
20-15	3281-3283	of	substance[170]	new[170]	_	_
20-16	3284-3290	nitric	substance[170]|abstract|substance[172]	new[170]|new|new[172]	_	_
20-17	3291-3296	oxide	substance[170]|substance[172]	new[170]|new[172]	_	_
20-18	3297-3298	(	_	_	_	_
20-19	3299-3301	NO	_	_	_	_
20-20	3302-3303	)	_	_	_	_
20-21	3304-3305	.	_	_	_	_

#Text=These and other studies proposed that the leading mechanism for the association between vitamin-D deficiency and CVD is related to endothelial dysfunction and impaired endothelial-dependent NO production .
21-1	3306-3311	These	event[173]	giv[173]	_	_
21-2	3312-3315	and	event[173]	giv[173]	_	_
21-3	3316-3321	other	event[173]	giv[173]	_	_
21-4	3322-3329	studies	event[173]	giv[173]	_	_
21-5	3330-3338	proposed	_	_	_	_
21-6	3339-3343	that	_	_	_	_
21-7	3344-3347	the	abstract[174]	new[174]	_	_
21-8	3348-3355	leading	abstract[174]	new[174]	_	_
21-9	3356-3365	mechanism	abstract[174]	new[174]	_	_
21-10	3366-3369	for	abstract[174]	new[174]	_	_
21-11	3370-3373	the	abstract[174]|abstract[175]	new[174]|giv[175]	_	_
21-12	3374-3385	association	abstract[174]|abstract[175]	new[174]|giv[175]	_	_
21-13	3386-3393	between	abstract[174]|abstract[175]	new[174]|giv[175]	_	_
21-14	3394-3403	vitamin-D	abstract[174]|abstract[175]|abstract[176]|abstract[177]	new[174]|giv[175]|giv[176]|giv[177]	_	_
21-15	3404-3414	deficiency	abstract[174]|abstract[175]|abstract[176]|abstract[177]	new[174]|giv[175]|giv[176]|giv[177]	_	_
21-16	3415-3418	and	abstract[174]|abstract[175]|abstract[177]	new[174]|giv[175]|giv[177]	_	_
21-17	3419-3422	CVD	abstract[174]|abstract[175]|abstract[177]|event	new[174]|giv[175]|giv[177]|giv	_	_
21-18	3423-3425	is	_	_	_	_
21-19	3426-3433	related	_	_	_	_
21-20	3434-3436	to	_	_	_	_
21-21	3437-3448	endothelial	abstract|abstract[180]	giv|giv[180]	_	_
21-22	3449-3460	dysfunction	abstract[180]	giv[180]	_	_
21-23	3461-3464	and	_	_	_	_
21-24	3465-3473	impaired	person[181]	new[181]	_	_
21-25	3474-3495	endothelial-dependent	person[181]	new[181]	_	_
21-26	3496-3498	NO	abstract[182]	giv[182]	coref	24-18[214_182]
21-27	3499-3509	production	abstract[182]	giv[182]	_	_
21-28	3510-3511	.	_	_	_	_

#Text=Despite this accumulating evidence of the role of vitamin D in vascular function , direct mechanistic evidence of this role in the microvasculature of morbidly obese population and how it might be modified following massive weight loss are largely unexplored .
22-1	3512-3519	Despite	_	_	_	_
22-2	3520-3524	this	abstract[183]	giv[183]	coref	22-15[187_183]
22-3	3525-3537	accumulating	abstract[183]	giv[183]	_	_
22-4	3538-3546	evidence	abstract[183]	giv[183]	_	_
22-5	3547-3549	of	abstract[183]	giv[183]	_	_
22-6	3550-3553	the	abstract[183]|abstract[184]	giv[183]|new[184]	coref	22-19[188_184]
22-7	3554-3558	role	abstract[183]|abstract[184]	giv[183]|new[184]	_	_
22-8	3559-3561	of	abstract[183]|abstract[184]	giv[183]|new[184]	_	_
22-9	3562-3569	vitamin	abstract[183]|abstract[184]|substance[185]	giv[183]|new[184]|giv[185]	coref	23-13[0_185]
22-10	3570-3571	D	abstract[183]|abstract[184]|substance[185]	giv[183]|new[184]|giv[185]	_	_
22-11	3572-3574	in	abstract[183]|abstract[184]|substance[185]	giv[183]|new[184]|giv[185]	_	_
22-12	3575-3583	vascular	abstract[183]|abstract[184]|substance[185]|abstract[186]	giv[183]|new[184]|giv[185]|new[186]	coref	24-10[212_186]
22-13	3584-3592	function	abstract[183]|abstract[184]|substance[185]|abstract[186]	giv[183]|new[184]|giv[185]|new[186]	_	_
22-14	3593-3594	,	_	_	_	_
22-15	3595-3601	direct	abstract[187]	giv[187]	_	_
22-16	3602-3613	mechanistic	abstract[187]	giv[187]	_	_
22-17	3614-3622	evidence	abstract[187]	giv[187]	_	_
22-18	3623-3625	of	abstract[187]	giv[187]	_	_
22-19	3626-3630	this	abstract[187]|abstract[188]	giv[187]|giv[188]	_	_
22-20	3631-3635	role	abstract[187]|abstract[188]	giv[187]|giv[188]	_	_
22-21	3636-3638	in	abstract[187]	giv[187]	_	_
22-22	3639-3642	the	abstract[187]|abstract[189]	giv[187]|new[189]	ana	22-30[0_189]
22-23	3643-3659	microvasculature	abstract[187]|abstract[189]	giv[187]|new[189]	_	_
22-24	3660-3662	of	abstract[187]|abstract[189]	giv[187]|new[189]	_	_
22-25	3663-3671	morbidly	abstract[187]|abstract[189]|person[190]	giv[187]|new[189]|giv[190]	_	_
22-26	3672-3677	obese	abstract[187]|abstract[189]|person[190]	giv[187]|new[189]|giv[190]	_	_
22-27	3678-3688	population	abstract[187]|abstract[189]|person[190]	giv[187]|new[189]|giv[190]	_	_
22-28	3689-3692	and	_	_	_	_
22-29	3693-3696	how	_	_	_	_
22-30	3697-3699	it	abstract	giv	coref	23-16[198_0]
22-31	3700-3705	might	_	_	_	_
22-32	3706-3708	be	_	_	_	_
22-33	3709-3717	modified	_	_	_	_
22-34	3718-3727	following	abstract[192]	giv[192]	coref	23-39[207_192]
22-35	3728-3735	massive	abstract[192]	giv[192]	_	_
22-36	3736-3742	weight	abstract[192]	giv[192]	_	_
22-37	3743-3747	loss	abstract[192]	giv[192]	_	_
22-38	3748-3751	are	_	_	_	_
22-39	3752-3759	largely	_	_	_	_
22-40	3760-3770	unexplored	_	_	_	_
22-41	3771-3772	.	_	_	_	_

#Text=The purpose of the current study is to investigate the effects of vitamin D on the microvasculature isolated from both subcutaneous ( SAT ) and visceral adipose tissue ( VAT ) in morbidly obese adults before and after bariatric surgery-induced weight loss .
23-1	3773-3776	The	abstract[193]	new[193]	_	_
23-2	3777-3784	purpose	abstract[193]	new[193]	_	_
23-3	3785-3787	of	abstract[193]	new[193]	_	_
23-4	3788-3791	the	abstract[193]|abstract[194]	new[193]|giv[194]	coref	27-8[231_194]
23-5	3792-3799	current	abstract[193]|abstract[194]	new[193]|giv[194]	_	_
23-6	3800-3805	study	abstract[193]|abstract[194]	new[193]|giv[194]	_	_
23-7	3806-3808	is	_	_	_	_
23-8	3809-3811	to	_	_	_	_
23-9	3812-3823	investigate	_	_	_	_
23-10	3824-3827	the	abstract[195]	giv[195]	coref	27-21[234_195]
23-11	3828-3835	effects	abstract[195]	giv[195]	_	_
23-12	3836-3838	of	abstract[195]	giv[195]	_	_
23-13	3839-3846	vitamin	abstract[195]|substance|person[197]	giv[195]|giv|giv[197]	coref|coref|coref|coref	24-6|24-6[210_197]|24-6|24-6[210_197]
23-14	3847-3848	D	abstract[195]|person[197]	giv[195]|giv[197]	_	_
23-15	3849-3851	on	abstract[195]|person[197]	giv[195]|giv[197]	_	_
23-16	3852-3855	the	abstract[195]|person[197]|abstract[198]	giv[195]|giv[197]|giv[198]	_	_
23-17	3856-3872	microvasculature	abstract[195]|person[197]|abstract[198]	giv[195]|giv[197]|giv[198]	_	_
23-18	3873-3881	isolated	abstract[195]	giv[195]	_	_
23-19	3882-3886	from	abstract[195]	giv[195]	_	_
23-20	3887-3891	both	abstract[195]|person[199]	giv[195]|new[199]	_	_
23-21	3892-3904	subcutaneous	abstract[195]|person[199]	giv[195]|new[199]	_	_
23-22	3905-3906	(	abstract[195]	giv[195]	_	_
23-23	3907-3910	SAT	abstract[195]|object	giv[195]|new	_	_
23-24	3911-3912	)	abstract[195]	giv[195]	_	_
23-25	3913-3916	and	abstract[195]	giv[195]	_	_
23-26	3917-3925	visceral	abstract[195]|object[202]	giv[195]|giv[202]	appos	23-30[0_202]
23-27	3926-3933	adipose	abstract[195]|abstract|object[202]	giv[195]|giv|giv[202]	_	_
23-28	3934-3940	tissue	abstract[195]|object[202]	giv[195]|giv[202]	_	_
23-29	3941-3942	(	_	_	_	_
23-30	3943-3946	VAT	object	giv	_	_
23-31	3947-3948	)	_	_	_	_
23-32	3949-3951	in	_	_	_	_
23-33	3952-3960	morbidly	person[204]	giv[204]	coref	24-13[213_204]
23-34	3961-3966	obese	person[204]	giv[204]	_	_
23-35	3967-3973	adults	person[204]	giv[204]	_	_
23-36	3974-3980	before	person[204]	giv[204]	_	_
23-37	3981-3984	and	person[204]	giv[204]	_	_
23-38	3985-3990	after	person[204]	giv[204]	_	_
23-39	3991-4000	bariatric	person[204]|abstract|abstract[207]	giv[204]|new|giv[207]	coref|coref	24-34[217_207]|24-34[217_207]
23-40	4001-4016	surgery-induced	person[204]|abstract[207]	giv[204]|giv[207]	_	_
23-41	4017-4023	weight	person[204]|place|abstract[207]	giv[204]|new|giv[207]	_	_
23-42	4024-4028	loss	person[204]|abstract[207]	giv[204]|giv[207]	_	_
23-43	4029-4030	.	_	_	_	_

#Text=The central hypothesis is that vitamin D would improve microvascular function in obese adults via improving flow-mediated NO production , and this effect would be of a greater magnitude before compared to after weight loss .
24-1	4031-4034	The	abstract[208]	new[208]	_	_
24-2	4035-4042	central	abstract[208]	new[208]	_	_
24-3	4043-4053	hypothesis	abstract[208]	new[208]	_	_
24-4	4054-4056	is	_	_	_	_
24-5	4057-4061	that	_	_	_	_
24-6	4062-4069	vitamin	substance|substance[210]	giv|giv[210]	_	_
24-7	4070-4071	D	substance[210]	giv[210]	_	_
24-8	4072-4077	would	_	_	_	_
24-9	4078-4085	improve	_	_	_	_
24-10	4086-4099	microvascular	abstract|abstract[212]	new|giv[212]	coref|coref|coref|coref	27-24|27-24[236_212]|27-24|27-24[236_212]
24-11	4100-4108	function	abstract[212]	giv[212]	_	_
24-12	4109-4111	in	abstract[212]	giv[212]	_	_
24-13	4112-4117	obese	abstract[212]|person[213]	giv[212]|giv[213]	_	_
24-14	4118-4124	adults	abstract[212]|person[213]	giv[212]|giv[213]	_	_
24-15	4125-4128	via	_	_	_	_
24-16	4129-4138	improving	_	_	_	_
24-17	4139-4152	flow-mediated	_	_	_	_
24-18	4153-4155	NO	abstract[214]	giv[214]	_	_
24-19	4156-4166	production	abstract[214]	giv[214]	_	_
24-20	4167-4168	,	_	_	_	_
24-21	4169-4172	and	_	_	_	_
24-22	4173-4177	this	abstract[215]	new[215]	_	_
24-23	4178-4184	effect	abstract[215]	new[215]	_	_
24-24	4185-4190	would	_	_	_	_
24-25	4191-4193	be	_	_	_	_
24-26	4194-4196	of	_	_	_	_
24-27	4197-4198	a	abstract[216]	new[216]	_	_
24-28	4199-4206	greater	abstract[216]	new[216]	_	_
24-29	4207-4216	magnitude	abstract[216]	new[216]	_	_
24-30	4217-4223	before	_	_	_	_
24-31	4224-4232	compared	_	_	_	_
24-32	4233-4235	to	_	_	_	_
24-33	4236-4241	after	_	_	_	_
24-34	4242-4248	weight	abstract[217]	giv[217]	_	_
24-35	4249-4253	loss	abstract[217]	giv[217]	_	_
24-36	4254-4255	.	_	_	_	_

#Text=In our previous work , we found that flow-induced dilation ( FID ) is impaired in morbidly obese individuals due to an imbalance of NO and H2O2 .
25-1	4256-4258	In	_	_	_	_
25-2	4259-4262	our	person|abstract[219]	acc|new[219]	ana|ana	25-6|25-6
25-3	4263-4271	previous	abstract[219]	new[219]	_	_
25-4	4272-4276	work	abstract[219]	new[219]	_	_
25-5	4277-4278	,	_	_	_	_
25-6	4279-4281	we	person	giv	ana	27-11
25-7	4282-4287	found	_	_	_	_
25-8	4288-4292	that	abstract[221]	new[221]	appos	25-12[0_221]
25-9	4293-4305	flow-induced	abstract[221]	new[221]	_	_
25-10	4306-4314	dilation	abstract[221]	new[221]	_	_
25-11	4315-4316	(	_	_	_	_
25-12	4317-4320	FID	abstract	giv	_	_
25-13	4321-4322	)	_	_	_	_
25-14	4323-4325	is	_	_	_	_
25-15	4326-4334	impaired	_	_	_	_
25-16	4335-4337	in	_	_	_	_
25-17	4338-4346	morbidly	person[223]	giv[223]	_	_
25-18	4347-4352	obese	person[223]	giv[223]	_	_
25-19	4353-4364	individuals	person[223]	giv[223]	_	_
25-20	4365-4368	due	_	_	_	_
25-21	4369-4371	to	_	_	_	_
25-22	4372-4374	an	abstract[224]	new[224]	_	_
25-23	4375-4384	imbalance	abstract[224]	new[224]	_	_
25-24	4385-4387	of	_	_	_	_
25-25	4388-4390	NO	abstract[225]	new[225]	coref	26-1[0_225]
25-26	4391-4394	and	abstract[225]	new[225]	_	_
25-27	4395-4399	H2O2	abstract[225]	new[225]	_	_
25-28	4400-4401	.	_	_	_	_

#Text=H2O2 may serve as a compensatory mechanism for vasodilation during pathological conditions such as obesity .
26-1	4402-4406	H2O2	abstract	giv	coref	27-27[237_0]
26-2	4407-4410	may	_	_	_	_
26-3	4411-4416	serve	_	_	_	_
26-4	4417-4419	as	_	_	_	_
26-5	4420-4421	a	_	_	_	_
26-6	4422-4434	compensatory	_	_	_	_
26-7	4435-4444	mechanism	_	_	_	_
26-8	4445-4448	for	_	_	_	_
26-9	4449-4461	vasodilation	substance[227]	new[227]	_	_
26-10	4462-4468	during	substance[227]	new[227]	_	_
26-11	4469-4481	pathological	substance[227]|abstract[228]	new[227]|new[228]	_	_
26-12	4482-4492	conditions	substance[227]|abstract[228]	new[227]|new[228]	_	_
26-13	4493-4497	such	substance[227]|abstract[228]	new[227]|new[228]	_	_
26-14	4498-4500	as	substance[227]|abstract[228]	new[227]|new[228]	_	_
26-15	4501-4508	obesity	substance[227]|abstract[228]|abstract	new[227]|new[228]|giv	_	_
26-16	4509-4510	.	_	_	_	_

#Text=Using the proposed ex vivo system in this study , we are able to explore the contributing vasoactive mediators of vitamin-D effects on microvascular function , mainly NO and H2O2 .
27-1	4511-4516	Using	_	_	_	_
27-2	4517-4520	the	abstract[230]	giv[230]	_	_
27-3	4521-4529	proposed	abstract[230]	giv[230]	_	_
27-4	4530-4532	ex	abstract[230]	giv[230]	_	_
27-5	4533-4537	vivo	abstract[230]	giv[230]	_	_
27-6	4538-4544	system	abstract[230]	giv[230]	_	_
27-7	4545-4547	in	_	_	_	_
27-8	4548-4552	this	abstract[231]	giv[231]	_	_
27-9	4553-4558	study	abstract[231]	giv[231]	_	_
27-10	4559-4560	,	_	_	_	_
27-11	4561-4563	we	person	giv	_	_
27-12	4564-4567	are	_	_	_	_
27-13	4568-4572	able	_	_	_	_
27-14	4573-4575	to	_	_	_	_
27-15	4576-4583	explore	_	_	_	_
27-16	4584-4587	the	person[233]	new[233]	_	_
27-17	4588-4600	contributing	person[233]	new[233]	_	_
27-18	4601-4611	vasoactive	person[233]	new[233]	_	_
27-19	4612-4621	mediators	person[233]	new[233]	_	_
27-20	4622-4624	of	person[233]	new[233]	_	_
27-21	4625-4634	vitamin-D	person[233]|abstract[234]	new[233]|giv[234]	_	_
27-22	4635-4642	effects	person[233]|abstract[234]	new[233]|giv[234]	_	_
27-23	4643-4645	on	person[233]|abstract[234]	new[233]|giv[234]	_	_
27-24	4646-4659	microvascular	person[233]|abstract[234]|abstract|abstract[236]	new[233]|giv[234]|giv|giv[236]	_	_
27-25	4660-4668	function	person[233]|abstract[234]|abstract[236]	new[233]|giv[234]|giv[236]	_	_
27-26	4669-4670	,	person[233]|abstract[234]	new[233]|giv[234]	_	_
27-27	4671-4677	mainly	person[233]|abstract[234]|abstract[237]	new[233]|giv[234]|giv[237]	_	_
27-28	4678-4680	NO	person[233]|abstract[234]|abstract[237]	new[233]|giv[234]|giv[237]	_	_
27-29	4681-4684	and	person[233]|abstract[234]|abstract[237]	new[233]|giv[234]|giv[237]	_	_
27-30	4685-4689	H2O2	person[233]|abstract[234]|abstract[237]	new[233]|giv[234]|giv[237]	_	_
27-31	4690-4691	.	_	_	_	_
